PHL has multi-locational manufacturing facilities dedicated to each segment of products, thus keeping complete control in cross-contamination, as recommended by the guidelines of World Health Organisation (WHO)Each plant is equipped with state-of-the-art manufacturing equipment’s and sophisticated analytical laboratories.
Our manufacturing facilities strictly follow current Good Manufacturing Practices (cGMP) as guided by the World Health Organization (WHO), including compliance with national and international regulations, industry standards and customer requirements.
Our multi-locational WHO-GMP approved manufacturing facilities are as below:
Dedicated General formulation unit..
- Lyophilisation
- Sterile-liquid ampoule / vial, dry powder
- Tablets, capsules and syrup
- Soft gelatine capsules
- Ointment, Creams & Aerosol
- Sterile Ophthalmic preparations for eye drops & ointments
- Effervescent Tablets
Beta Lactum facility.
- Oral solids
- Injectable
Dedicated Cephalosporin formulation unit..
- Injectable
- Tablets & capsules
Dedicated Oncology formulation unit.
- Lyophilisation
- Sterile-liquid ampoule / vial, dry powder
- Tablets & capsules
Dedicated Hormonal formulation unit.
- Lyophilisation
- Sterile-liquid ampoule / vial
- Tablets & capsules
CYTOTOXIC
TABLETS
175 million
CAPSULE
10 million
LYOPHILIZED INJECTION
5 million (w.r.t. 10 ml)
LIQUID INJECTION
10 million (w.r.t. 10 ml)
CEPHALO-SPORIN
DRY POWDER INJECTION
10 million
GENERAL
TABLETS
250 million
CAPSULE
20 million
AMPOULE
50,000/shift
DRY SYRUP
12 million (100 ml)
OINTMENT TUBE
6 million